Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and OCD

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT02713516
Collaborator
(none)
40
1
1
10
4

Study Details

Study Description

Brief Summary

Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. Investigators aim to enhance this therapy with the use of virtual reality exposures and to make therapy more available and accessible for patients with anxiety disorders. The societal benefit of increased access to therapy is that, if successful, it will increase the number of patients who receive appropriate treatment for an anxiety disorder.

Condition or Disease Intervention/Treatment Phase
  • Other: Virtual Reality
N/A

Detailed Description

Twenty children with CADs or OCD who have received less than 3 treatment sessions and a parent will be recruited to pilot the VR system. Participants will be identified through the Mayo Clinic Pediatric Anxiety Disorders Clinic. Each patient will participate in a single (up to) 2-hour visit. During the first 30 minutes the patient and parent will be introduced to the VR system and the rationale for this feasibility study. Next, a therapist will lead the patient through exposure exercises using the VR system for up to 30 minutes. During the next period, up to 30 minutes, the therapist will go to a different room and the patient, with support from their parent, will complete exposure exercises using the VR system that the therapist directed them to complete. During the exposures the interviewer will observe, code and record the patient's interaction with the VR system. For the remaining time (up to 30 minutes) the interviewer will interview the patient about his or her experience with the VR system and then will ask for observations and opinions from the parent.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Low-Cost, Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and Obsessive Compulsive Disorders
Actual Study Start Date :
Aug 1, 2017
Actual Primary Completion Date :
May 1, 2018
Actual Study Completion Date :
May 31, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single Arm

The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.

Other: Virtual Reality
Use of virtual reality to deliver exposure therapy
Other Names:
  • Google Cardboard
  • Outcome Measures

    Primary Outcome Measures

    1. Mean change from baseline in Subjective Units of Distress Scale (SUDS) at end of session [approximately 2 hours]

      The SUDS - 0 to 10 ratings, where 0 indicates that they feel no anxiety at all and 10 indicates that they are experiencing maximum distress

    Secondary Outcome Measures

    1. Percent of children to describe the virtual reality system as engaging and easy to use based on qualitative interviews [approximately 2 hours]

      The ease of use of the VR system

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    7 Years to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Age 7 to 12

    2. Primary diagnosis of anxiety, generalized anxiety disorder, social phobia, separation anxiety and/or OCD

    Exclusion Criteria:
    1. History of and/or current diagnosis of: psychosis, autism, bipolar disorder, mental retardation, oppositional defiant disorder, PTSD, selective mutism or major depressive disorder.

    2. Current suicidality or recent suicidal behavior

    3. Parent to be involved in study who is unable to adequately participate due to intellectual or psychiatric difficulties

    4. Starting or changing the dosage of a psychiatric medication in the last 2 months

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Stephen P Whiteside, PhD., L.P., Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Stephen Whiteside, Associate Professor of Psychology, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT02713516
    Other Study ID Numbers:
    • 15-008235
    First Posted:
    Mar 18, 2016
    Last Update Posted:
    Nov 13, 2018
    Last Verified:
    Nov 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Stephen Whiteside, Associate Professor of Psychology, Mayo Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 13, 2018